Oasmia Pharmaceutical AB
OASM
OASM was delisted on the 21st of August, 2019.
4 hedge funds and large institutions have $38K invested in Oasmia Pharmaceutical AB in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 5 closing their positions.
50% less funds holding
Funds holding: 8 → 4 (-4)
80% less capital invested
Capital invested by funds: $187K → $38K (-$149K)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
FNY Investment Advisers
New York
|
+$4.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$50K |
| 2 |
Jane Street
New York
|
-$27K |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$24K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.63K |
OASM Hedge Fund Activity: Q2 2019 in Review
4 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Oasmia Pharmaceutical AB (OASM) for Q2 2019, worth a combined $38K — down 80% from $187K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of OASM and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was FNY Investment Advisers, opening a new position worth an estimated $4.7K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $50K sold.
- 4 institutional investors held Oasmia Pharmaceutical AB (OASM) as of Q2 2019, down from 8 in Q1 2019.
- Funds reported $38K of Oasmia Pharmaceutical AB stock for Q2 2019, down 80% quarter-over-quarter.
- 1 fund opened new Oasmia Pharmaceutical AB positions in Q2 2019 and 5 closed out, a net change of -4 holders.
- The largest Oasmia Pharmaceutical AB buyer in Q2 2019 was FNY Investment Advisers, an estimated $4.7K added.
- The largest Oasmia Pharmaceutical AB seller in Q2 2019 was Susquehanna International Group, an estimated $50K sold.
Based on aggregated 13F filings for Q2 2019.